CD86 and neoplasm: In accordance with this potential TIL and TAM cooperation, some authors have reported that monocytes with a phenotype similar to anti-tumor TAMs, i.e., expressing CD16, HLA-DR, PD-L1 and CD86, can be found at the baseline and during immunotherapy in the blood of cancer patients responding to immune checkpoint inhibitors [66,71,72,73], suggesting that these cells might be the precursors of M1-like TAMs found at the tumor site.